What is CytoSMART Technologies?
CytoSMART Technologies operates within the advanced life sciences sector, focusing on live-cell analysis platforms. These technologies are crucial for providing researchers with deep insights into human biology, thereby accelerating discoveries in disease research and the development of novel therapeutics. The company's product suite is designed to monitor cellular activity in real-time, supporting critical applications across neurology, oncology, cardiology, and virology. By offering non-invasive, efficient analysis tools, CytoSMART empowers leading pharmaceutical companies and academic institutions to capture complex cellular dynamics with greater precision.
How much funding has CytoSMART Technologies raised?
CytoSMART Technologies has raised a total of $5.9M across 1 funding round:
Unspecified
$5.9M
Unspecified (2019): $5.9M with participation from Eindhoven Venture Capital, Holland Capital, and BOM Brabant Ventures
Key Investors in CytoSMART Technologies
Eindhoven Venture Capital
Eindhoven Venture Capital is an investment firm that likely focuses on technology and innovation within the region, providing capital to promising startups and established companies.
Holland Capital
Holland Capital is an actively involved investment company focused on supporting the growth of SMEs in the Technology, Healthcare, and Agrifood sectors through venture, growth, and buy-out investments. The firm aims to enhance economic impact by investing in companies that drive technological innovation and improve efficiency in existing operations.
BOM Brabant Ventures
De Brabantse Ontwikkelings Maatschappij (BOM) is dedicated to catalyzing change by supporting startups and scale-ups in Brabant through investment, knowledge, and networking. They focus on developing innovative solutions in key areas such as sustainable food, health, climate-neutral energy, and advanced technologies.
What's next for CytoSMART Technologies?
The substantial enterprise-level funding indicates a strategic pivot towards scaling operations and potentially expanding market reach for CytoSMART Technologies. This capital infusion is likely to fuel further research and development, enhance product innovation, and strengthen its competitive position in the live-cell analysis market. The company is poised to leverage this financial backing to solidify its role as a key enabler of scientific advancement, driving progress in critical areas of medical research and drug discovery.
See full CytoSMART Technologies company page
